Cwm LLC Increases Holdings in Alignment Healthcare, Inc. $ALHC

Cwm LLC boosted its position in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 349.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 39,511 shares of the company’s stock after purchasing an additional 30,711 shares during the period. Cwm LLC’s holdings in Alignment Healthcare were worth $689,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Invesco Ltd. raised its position in Alignment Healthcare by 122.3% during the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after buying an additional 2,294,739 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Alignment Healthcare by 173.3% in the second quarter. Marshall Wace LLP now owns 2,039,714 shares of the company’s stock worth $28,556,000 after acquiring an additional 1,293,416 shares during the period. Voya Investment Management LLC increased its stake in shares of Alignment Healthcare by 61.0% in the third quarter. Voya Investment Management LLC now owns 3,196,297 shares of the company’s stock worth $55,775,000 after acquiring an additional 1,210,930 shares during the period. Qube Research & Technologies Ltd raised its holdings in shares of Alignment Healthcare by 269.6% during the second quarter. Qube Research & Technologies Ltd now owns 1,523,986 shares of the company’s stock worth $21,336,000 after purchasing an additional 1,111,685 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Alignment Healthcare by 124.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,869,035 shares of the company’s stock valued at $26,166,000 after purchasing an additional 1,037,638 shares during the period. Institutional investors and hedge funds own 86.19% of the company’s stock.

Insider Activity at Alignment Healthcare

In other Alignment Healthcare news, CEO John E. Kao sold 605,648 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $18.74, for a total transaction of $11,349,843.52. Following the completion of the sale, the chief executive officer directly owned 2,234,294 shares in the company, valued at approximately $41,870,669.56. The trade was a 21.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph S. Konowiecki sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $18.00, for a total value of $450,000.00. Following the completion of the transaction, the director owned 1,085,973 shares in the company, valued at approximately $19,547,514. This trade represents a 2.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,098,532 shares of company stock worth $39,617,538 in the last quarter. Company insiders own 7.00% of the company’s stock.

Alignment Healthcare Trading Down 1.7%

Shares of ALHC stock opened at $20.93 on Thursday. Alignment Healthcare, Inc. has a 1-year low of $11.48 and a 1-year high of $21.65. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -174.42, a PEG ratio of 6.12 and a beta of 1.16. The company has a debt-to-equity ratio of 1.99, a current ratio of 1.61 and a quick ratio of 1.61. The stock has a 50 day simple moving average of $18.55 and a 200-day simple moving average of $16.46.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. The company had revenue of $993.70 million during the quarter, compared to analyst estimates of $980.90 million. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The firm’s revenue was up 43.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.14) EPS. On average, equities research analysts expect that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent quarterly results showed revenue strength and an EPS beat (Qtr revenue ≈ $993.7M, +43.5% YoY; EPS $0.02 vs. consensus -$0.01), which supports growth expectations and helps explain upside interest from investors. Read More.
• Neutral Sentiment: Analyst coverage is active — some firms have raised price targets (consensus ~$21.25) while others remain neutral; Benzinga’s analyst roundup could amplify moves if any major upgrades or target changes are published. Read More.
• Negative Sentiment: Large insider sales were disclosed this week, including significant dispositions by President Dawn Maroney (100,000 shares sold ~Jan 2 and a separate filing showing 228,152 shares sold) and other executives (Christopher Joyce, Hyong Kim). Investors often interpret material executive selling near highs as profit-taking or reduced insider conviction, which can pressure the stock. Read More. • Read More.
• Negative Sentiment: A recent valuation-focused piece raises the question of whether current valuations already price in expected growth, signalling potential overpaying risk for new buyers if execution slows or multiples compress. That stokes caution even with solid top-line growth. Read More.

Wall Street Analyst Weigh In

ALHC has been the topic of several analyst reports. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. KeyCorp restated an “overweight” rating on shares of Alignment Healthcare in a research note on Monday, November 24th. Zacks Research cut Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. The Goldman Sachs Group restated a “buy” rating and issued a $22.00 price objective on shares of Alignment Healthcare in a research report on Monday, November 3rd. Finally, UBS Group lifted their target price on shares of Alignment Healthcare from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.25.

Alignment Healthcare Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.